SPDR Biotech ETF +2.0%
Why now
Thesis: Small-cap biotech strength signals rotation
Catalyst to watch: M&A or trial readouts in sector
Main risk: Rate rise could reverse biotech gains
Why it matters
Equal-weighted biotech outperformance signals broad small-cap biotech demand.
Details
SPDR Biotech ETF (XBI) moved +2.0% in the latest period (1d). Close: 161.37, prior: 158.23.
Sources
- yfinance · finance.yahoo.com · 2026-09-23 00:00 UTC